Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

Exscientia, a UK-based drug discovery technology spinout of University of Dundee, obtained $60m in a series C round today led by pharmaceutical firm Novo Holdings.
Drug discovery and development company Evotec, pharmaceutical firm Bristol-Myers Squibb and private equity firm GT Healthcare Capital, through unnamed limited partners, also took part in the round.
Incorporated in 2012, Exscientia exploits artificial intelligence technology for a drug discovery platform that taps into the outcomes of historic research to design compounds and rapidly…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in